For the quarter ending 2025-09-30, CTMX made $5,963K in revenue. -$14,158K in net income. Net profit margin of -237.43%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenues | 5,963 | 18,658 | 50,917 | 34,890 |
| Research and development | 15,304 | 13,322 | 18,868 | 20,671 |
| General and administrative | 6,427 | 6,622 | 9,428 | 7,258 |
| Total operating expenses | 21,731 | 19,944 | 28,296 | 27,929 |
| Income (loss) from operations | -15,768 | -1,286 | 22,621 | 6,961 |
| Interest income | 1,592 | 1,178 | 955 | 1,814 |
| Other (expense) income, net | 5 | 17 | 11 | -10 |
| Income (loss) before income taxes | -14,171 | -91 | 23,587 | 8,765 |
| Provision for income taxes | 58 | 63 | 62 | 54 |
| Net income (loss) | -14,229 | -154 | 23,525 | 8,711 |
| Unrealized (loss) gain on investments, net of tax | 71 | 34 | -28 | -37 |
| Total comprehensive income (loss) | -14,158 | -120 | 23,497 | 8,674 |
| Weighted average number of shares outstanding, basic | 165,004,291 | 129,075,546 | 87,121,502 | -217,974.667 |
| Weighted average number of shares outstanding, diluted | 165,004,291 | 129,075,546 | 87,150,666 | -153,197.667 |
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)